RNAC Cartesian Therapeutics, Inc.

NASDAQ
$7.41

Cartesian Therapeutics, Inc. (RNAC) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $1.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.6% since its last earnings release on August 6, 2026.

Cartesian Therapeutics Beat Consensus Estimates
Thursday, August 6, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($1.02)
Rev est $250K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.